Keyword: Five Prime Therapeutics
The cuts will leave Five Prime with a “small research group” focused on taking clinical candidates forward with the help of service providers.
Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics CEO Aron Knickerbocker is exiting the company.
CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs.
Immuno-oncology player Five Prime is axing 20% of its workforce and its early-stage R&D in order to focus on its clinical cancer programs.
BMS is combining Opdivo and cabiralizumab, an anti-CSF-1 antibody, with Apexigen’s lead CD40 activator in an early-phase solid tumor study.
Immuno-oncology biotech Five Prime has outlicensed a medication from its protein discovery platform exclusively to Belgium biopharma UCB.
Andrew Witty will lead Optum as CEO, Novartis' operations lead André Wyss steps down, Gilead bids farewell to longtime R&D lead Norbert Bischofberger.
Aron Knickerbocker will helm Five Prime, Hallberg becomes Sobi's general counsel, Truckenmiller promoted to EMD Serono's SVP.
Five Prime Therapeutics has tapped into its existing management to replace current president and CEO Rusty Williams.
After just two years, Five Prime Therapeutics has ducked out of an immuno-oncology collaboration with InhibRx that on signing had a value of more than $460 million.